Released May 9, 2022, after the close
10-Q filed May 9, 2022, 39 days after period end · 0000950170-22-008531
Q1 2022 · 10-Q
Revenue$5.90M$5.90M −59.8% vs Q1 2021−44.6% vs Q4 2021
Net Income-$39.11M-$39.11M N/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.84-$0.84 N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$39,132,000N/M
Operating Cash Flow-$35,255,000N/M
Margins · derived
Operating margin-663.6%−533.9 pt vs Q1 2021
Net margin-663.2%−456.1 pt vs Q1 2021
What the release said
The release
Same quarter
| Metric | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|
| Revenue | $5.90M | $14.66M | $7.15M | $8.63M |
| Net Income | -$39.11M | -$30.36M | -$19.60M | -$14.25M |
| EPS Diluted | -$0.84 | -$0.66 | -$0.84 | -$0.62 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR